Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Cert. of designation
Director comp.
|
|
Scilex Holding Co
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 10/02/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/27/2023 |
8-K/A
| Entry into a Material Definitive Agreement Interactive Data |
| 09/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...|
Docs:
|
"Senior Secured Promissory Note issued to Oramed Pharmaceuticals, Inc",
"Form of Scilex Holding Company Warrant to Purchase Common Stock",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of September 21, 2023, between Scilex Holding Company, a Delaware corporation , Oramed Pharmaceuticals, Inc., a Delaware corporation as the initial purchaser , and the Agent. WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Initial Purchaser, and the Initial Purchaser, desires to purchase from the Company, a promissory note and certain Warrants of the Company as more fully described in this Agreement; and WHEREAS, contemporaneous with the execution of this Agreement, the Initial Purchaser, Sorrento, Scintilla Pharmaceuticals, Inc. and the Company entered into t...",
"Registration Rights Agreement, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc",
"SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of September 21, 2023 , made by each of the signatories hereto in favor of the holders of that certain Senior Secured Promissory Note dated as of the date hereof due March 21, 2025 in the original aggregate principal amount of $101,875,000.00 and any Additional Notes issued by Scilex Holding Company, a Delaware corporation . W I T N E S S E T H: WHEREAS, pursuant to the Securities Purchase Agreement dated as of the date hereof, among Oramed Pharmaceuticals Inc. , Acquiom Agency Services LLC, as the collateral agent and the Company , the Company has agreed to sell and issue to the Inital Note Holder, and the Initial Note Holder has agreed to purchase from the Company the Note, subject to the terms and conditions set forth therein; and WHER...",
"Security Agreement, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC",
"Subordination Agreement, by and among eCapital Health Corp., Scilex Pharmaceuticals Inc. and Acquiom Agency Services LLC",
"Schedule I",
"Assignment, Assumption and Release Agreement, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc",
"Exhibit 10.8" |
|
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/05/2023 |
8-K
| Quarterly results |
| 06/01/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/05/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/21/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 02/06/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events, Financial Statements and Exhibits &nbs... |
| 02/02/2023 |
8-K
| Quarterly results |
| 02/02/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/30/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 01/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/17/2022 |
8-K
| Certificate of designation filed, Director compensation was amended/approved|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"State of Delaware Secretary of State Division of Corporations Delivered 08:01 AM 11/10/2022 FILED 08:01 AM 11/10/2022 SR 20223985377 - File Number 7129127 RESTATED CERTIFICATE OF INCORPORATION OF SCILEX HOLDING COMPANY a Delaware corporation",
"CERTIFICATE OF DESIGNATIONS OF SCILEX HOLDING COMPANY a Delaware corporation",
"BYLAWS OF SCILEX HOLDING COMPANY",
"AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"SCILEX HOLDING COMPANY 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: October 17, 2022 APPROVED BY THE STOCKHOLDERS: November 9, 2022 EFFECTIVE DATE: November 9, 2022 1. GENERAL. Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. Available Awards. The Plan provides for the grant of the following Awards: Incentive Stock Options; Nonstatutory Stock Options; SARs; Restricted Stock Awards; RSU Awards; Performance Awards; and Other Aw...",
"SCILEX HOLDING COMPANY STOCK OPTION GRANT NOTICE",
"SCILEX HOLDING COMPANY RSU AWARD GRANT NOTICE",
"SCILEX HOLDING COMPANY 2022 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: October 17, 2022 APPROVED BY THE STOCKHOLDERS: November 9, 2022 EFFECTIVE DATE: November 9, 2022 1. GENERAL; PURPOSE. The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. The Plan includes two components: a 423 Component and a Non-423 Component. The Company intends the 423 Component to qualify as..." |
|
| 11/09/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/31/2022 |
8-K
| Quarterly results |
| 10/18/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 04/11/2022 |
8-K/A
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even...|
Docs:
|
"PROMISSORY NOTE",
", April 11, 2022 -- Vickers Vantage Corp. I , a Cayman Islands exempted company, announced today that it has further extended the time it has to consummate an initial business combination by an additional three months pursuant to the Company’ s Amended and Restated Memorandum and Articles of Association. In connection with the extension, the Company’ s sponsors have deposited an aggregate of $1,035,000 into the trust account established in connection with the Company’ s initial public offering. The deposit was made in the form of a non-interest bearing loan. If the Company completes an initial business combination, the Company will repay such loaned amounts. If the Company does not complete a business combination, it will repay such loans only from funds held outside of the trust account. ..." |
|
| 04/11/2022 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even... |
| 03/18/2022 |
8-K
| Director compensation was amended/approved|
Docs:
|
"Vickers Vantage Corp. I 1 Harbourfront Avenue, #16-06 Keppel Bay Tower, Singapore 098632 Singapore",
"AGREEMENT AND PLAN OF MERGER",
"SPONSOR SUPPORT AGREEMENT",
"COMPANY STOCKHOLDER SUPPORT AGREEMENT",
"SCILEX HOLDING COMPANY, A MAJORITY-OWNED SUBSIDIARY OF SORRENTO THERAPEUTICS, INC., TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH VICKERS VANTAGE CORP. I ● Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before expenses, assuming no redemptions from Vickers Vantage Corp. I’ s existing public shareholders, which would provide the current stockholders of Scilex an estimated ownership of approximately 88% of the outstanding shares of the Combined Company. Merger expected to close by the third quarter of 2022, and the Combined Company’ s common stock is expected to be listed on Nasdaq under the new ticker symbol “SCLX” ● Funds will be used ...",
"Exhiibit 99.2 FOR IMMEDIATE RELEASE Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity ● SP-102 , with 401 patients enrolled in the C.L.E.A.R. trial experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistically significant improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean difference -1.08 , with a p-value ● SP-102 showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was ...",
"Investor Presentation" |
|
| 02/18/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|
|
|